Yu.B. Yurasova

Yu.B. Yurasova

Auto-generated profile, based on publicly available information

Yu.B. Yurasova

National medical research center for traumatology and orthopedics named after N.N. Priorov

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
APAlexander Sergeevich Pankratov
Alexander Sergeevich Pankratov
Irina S. FadeevaIrina S. Fadeeva
Irina S. Fadeeva
YYYulia B. Yurasova
Yulia B. Yurasova
VGVasily M. Grinin
Vasily M. Grinin
ICIgor Cherkesov
Igor Cherkesov
ЮБЮрасова Юлия Борисовна
Юрасова Юлия Борисовна
Today autografts are considered to be an optimal material for bone grafting. However, the collection of material and its clinical use is associated with several serious drawbacks, and therefore, in reconstructive surgery, a search for alternative treatment approaches is being conducted. A bone transplant from another person (allo-osteoplasty) is the most natural and logical option for replacing an autobone. Since 1965, allogeneic implants of a partially demineralized bone matrix combining osteoinductive and osteoconductive action have been used in clinical practice. However, the clinical results of the use of this material turned out to be ambiguous, which is due, first of all, to the significant variability of the osteoplastic potential of its various samples. For this reason, in clinical practice, sometimes preference is given to samples of non-demineralized allobone, which retain its structure longer. In this paper, we consider factors affecting the osteoinductive activity of a partially demineralized bone matrix, related both to the technological issues of its preparation and to the clinical conditions of use. Issues of the possible improvement of this material were discussed with a view to its further use in medical practice.

12 January 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
SMS. V. Mikhaylova
S. V. Mikhaylova
ASA. N. Slateckay
A. N. Slateckay
EPE. A. Pristanskova
E. A. Pristanskova
KKKirill Kirgizov
Kirill Kirgizov
OMO. V. Mendelevich
O. V. Mendelevich
ESE. V. Skorobogatova
E. V. Skorobogatova
Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme. MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the gold standard for the treatment of MPS I-H in patients diagnosed and treated before 2–2.5 years of age, having a high rate of success. Enzyme replacement therapy (ERT) with human recombinant laronidase has also been demonstrated to be effective in ameliorating the clinical conditions of pre-transplant MPS I-H patients and in improving HSCT outcome, by peri-transplant co-administration. Nevertheless the long-term clinical outcome even after successful HSCT varies considerably, with a persisting residual disease burden. This review will focus on all these critical issues related to the management of MPS I-H.

15 December 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
SMS.V. Mikhailova
S.V. Mikhailova
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
YYYu.B. Yurasova
Yu.B. Yurasova
MRMoscow N.N. Priorov National Medical Center Of Traumatology And Orthopedics Of The Ministry Of Healthcare Of Russia
Moscow N.N. Priorov National Medical Center Of Traumatology And Orthopedics Of The Ministry Of Healthcare Of Russia
EPE.E. Petryaykina
E.E. Petryaykina
Hypomagnesaemias are the diseases characterized by the reduced level of magnesium in the body. The first mention of them appeared in the early XX century when cases in children were initially described as conditions accompanied by painful twitching in the muscles, weakness and heart rhythm disturbances, the reasons for which remained unknown for a long time. The scientific research in recent decades has only made it possible to decipher the diseases’ pathogenesis mechanisms. Primary hypomagnesaemias are hereditary monogenic diseases in which, as a result of a violation of magnesium metabolism in the body, its concentration decreases and the main clinical manifestations of the disease develop. The clinical picture of hypomagnesemia in children can be diverse and nonspecific. Early symptoms are manifested in the form of short-term involuntary painful contractions of muscles or muscle groups, weakness, cardiac arrhythmia and fatigue. As the disease progresses, more rather serious symptoms such as stunted growth, psychomotor development and epileptic seizures may occur. The severity of clinical manifestations of hereditary hypomagnesaemias correlates with the degree and duration of magnesium deficiency: from general weakness and crumpy syndrome to the development of depression of consciousness and in some cases of an unfavorable outcome. The main methods for confirmatory diagnosis of genetically determined hypomagnesaemias are molecular genetic methods. Authors represent bibliographical review and recent updates on known primary hypomagnesaemias in terms of mechanisms of pathogenesis and clinical presentation as well as their own familial case description of hypomagnesaemia in children.

10 December 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
SMS.V. Mikhaylova
S.V. Mikhaylova
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
MZM.V. Zazhivikhina
M.V. Zazhivikhina
NVN.A. Votyakova
N.A. Votyakova
MAM.E. Abdullina
M.E. Abdullina
EPE.E. Petryaykina
E.E. Petryaykina
Pyruvate dehydrogenase complex deficiency (PDC) is a mitochondrial disease associated with a violation of pyruvate metabolism and leading to a decrease in ATP production. PDC is responsible for the decarboxylation of pyruvate into acetyl-CoA. PDC deficiency can be caused by changes in any of the genes encoding its subunits. The clinical phenotype is very variable, mainly the central nervous system is affected. Diagnosis of the disease can cause significant difficulties due to the rarity of the pathology, the lack of specificity of clinical symptoms and pronounced clinical polymorphism. The purpose of this research was to describe and discuss the clinical, biochemical and genetic data of six recently observed patients with PDC deficiency who were identified in Russia. Authors have analyzed the clinical manifestations of a rare progressive pathology from the group of mitochondrial diseases caused by pathogenic variants of the nuclear X-linked PDHA1 gene (encodes the alpha subunit of pyruvate dehydrogenase) in six patients aged 8 to 120 months old. By the time of examination in the hospital the main clinical symptoms included as follows: delayed psychomotor development, epileptic seizures, severe delay in psychomotor development and - in a single patient - depression of consciousness to coma, the status of epileptic seizures and an unfavorable outcome. In all patients, magnetic resonance imaging (MRI) of the brain revealed changes as follows: cortical atrophy in all 6 patients, basal ganglia lesion in three cases, congenital brain defects in 3 patients and multicystic lesion in a single patient. All children had high lactate levels. Pathogenic variants of the PDHA1 gene were detected in all 6 children and on this basis the diagnosis was confirmed. As a result of treatment, 5 of the 6 children showed moderate positive dynamics as follows: a decrease in the frequency of epileptic seizures and lactate in the blood, improvement in psychomotor development and - in a single patient - a fatal outcome as a result of late diagnosis and rapidly progressing clinical symptoms. Conclusion: Authors have described the clinical characteristics of PDC in recent cases such as: age of manifestation, the disease course nature, results of molecular genetic studies. Clinical polymorphism in patients with this rare pathology was shown as well. The Article may be of great help to pediatricians, neurologists and geneticists in improving the diagnosis of PDC deficiency.